ADC Development Services Targeting ENPP3

Antibody-drug conjugates (ADCs) represent a novel and promising class of biotherapeutics for the treatment of cancer. Potent drugs combine with antibodies through suitable linkers to generate specific therapeutic molecules-ADC, in which the antibody confers cell specificity and extended serum half-life while the payload displays a potent antitumor activity. Creative Biolabs is committed to developing high-quality ADC based on our advanced technology platforms. Our ADCs development services include the production of specific antibody, the synthesis of quality-guaranteed linker-payload and effective conjugation. We believe our services will promote your innovative cancer treatment.

Introduction of ENPP3

ENPP3 (ectonucleotide pyrophosphatase/phosphodiesterase 3), also known as CD203c, is a type II transmembrane protein as an enzyme in human. It is encoded by the ENPP3 gene and belongs to the ectonucleotide pyrophosphatases/phosphodiesterases family serving as a basophil activation marker. ENPP3 protein is composed of an extracellular domain, a nuclease-like domain, a catalytic domain and a somatomedin B-like domain. ENPP3 plays a role in glycosyltransferase activity through hydrolyzing extracellular pyrophosphate, phosphodiester bonds and intracellular nucleotides. It is expressed by neoplastic mast cells during mastocytosis, acute basophilic leukemia, colon cancer, and bile duct, and it has been found highly expressed in renal cell carcinoma (RCC) while low or absent in normal tissues. Thus, ENPP3 is considered as a potential target for the treatment of RCC.

Fig.1 Crystal structure and substrate binding mode of ENPP3.^1,2

What Can We Do for You?

Creative Biolabs offers ADCs development services against the ENPP3 biomarker to accelerate your drug discovery program. It is our commitment to give you high-quality products with fast turnaround time. Our experienced scientist team along with our broad services portfolio makes it easier to meet your specific requirements. Dedicated ADC experts in Creative Biolabs will provide you reliable services and strict quality controls under the most competitive price. Our ADCs services include ADC Antibody Screening, DrugLnk™ Custom Synthesis, Antibody Design and Conjugation, ADC in vitro Analysis and ADC in vivo Analysis.

If you have any special requirements related to ADCs, please feel free to contact us. We are looking forward to working together with your attractive projects.

References

1. Döhler, Christoph, Matthias Zebisch, and Norbert Sträter. "Crystal structure and substrate binding mode of ectonucleotide phosphodiesterase/pyrophosphatase-3 (NPP3)." Scientific Reports 8.1 (2018): 10874.
2. Distributed under Open Access License CC BY 4.0, without modification.